Want to see HK:1345 full AI Analyst Report?
1345 Stock Chart & Stats
HK$2.24
-HK$0.01(-0.45%)
At close: 4:00 PM EDT
HK$2.24
-HK$0.01(-0.45%)
Day’s Range― - ―
52-Week RangeHK$1.59 - HK$2.40
Previous CloseN/A
Volume69.00K
Average Volume (3M)54.17K
Market Cap
HK$2.64B
Enterprise ValueHK$2.23B
Total Cash (Recent Filing)HK$210.74M
Total Debt (Recent Filing)HK$121.44M
Price to Earnings (P/E)19.0
Beta0.20
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.36%
Share Statistics
EPS (TTM)0.10
Shares Outstanding1,257,447,000
10 Day Avg. Volume73,600
30 Day Avg. Volume54,166
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)2.33
Price to Sales (P/S)1.90
P/FCF Ratio12.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low debt-to-equity (~0.12) and a sizeable equity base give the company durable financial flexibility. Over the next 2–6 months this reduces refinancing and liquidity risk, supports steady operations, and preserves optionality for capex, R&D or opportunistic M&A without stressing cash flows.
Strong Free Cash Flow TrendRecent rising free cash flow and positive TTM operating cash flow improve the firm’s ability to self-fund operations, dividends and investment. This cash-generation strength provides a durable buffer against cyclical revenue weakness and supports capital allocation choices over the medium term.
Healthy Margins / Product MixHigh gross margins (~49%) and a positive net margin (~9%) indicate underlying pricing power or a favorable product mix typical in specialized pharma. These margins support long-term profitability and reinvestment capacity, helping sustain cash flow even if top-line growth is uneven.
Bears Say
Declining Revenue TrendA continuing top-line decline reduces operational leverage and constrains the company’s ability to scale fixed-cost investments. Persisting revenue weakness over the next several quarters can pressure margins, limit reinvestment in growth initiatives, and undermine longer-term competitive positioning.
Eroding Returns On EquityROE falling from prior highs to ~11% signals reduced capital efficiency and weaker profitability relative to historical performance. If this trend continues it will impair the company’s ability to generate attractive shareholder returns and may constrain dividend or reinvestment policies over the medium term.
Volatile Cash-flow HistoryHistorical volatility—including negative operating and free cash flow in 2023—raises execution risk and reduces predictability of funding for operations and dividends. Even with recent improvement, this volatility makes near-term planning and capital allocation less reliable and increases reliance on balance-sheet flexibility.
Shanghai Pioneer Holding Ltd News
1345 FAQ
What was Shanghai Pioneer Holding Ltd’s price range in the past 12 months?
Shanghai Pioneer Holding Ltd lowest stock price was HK$1.59 and its highest was HK$2.40 in the past 12 months.
What is Shanghai Pioneer Holding Ltd’s market cap?
Shanghai Pioneer Holding Ltd’s market cap is HK$2.64B.
When is Shanghai Pioneer Holding Ltd’s upcoming earnings report date?
Shanghai Pioneer Holding Ltd’s upcoming earnings report date is Sep 02, 2026 which is in 28 days.
How were Shanghai Pioneer Holding Ltd’s earnings last quarter?
Shanghai Pioneer Holding Ltd released its earnings results on Mar 30, 2026. The company reported HK$0.063 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.063.
Is Shanghai Pioneer Holding Ltd overvalued?
According to Wall Street analysts Shanghai Pioneer Holding Ltd’s price is currently Overvalued.
Does Shanghai Pioneer Holding Ltd pay dividends?
Shanghai Pioneer Holding Ltd pays a Semiannually dividend of HK$0.054 which represents an annual dividend yield of 5.36%. See more information on Shanghai Pioneer Holding Ltd dividends here
What is Shanghai Pioneer Holding Ltd’s EPS estimate?
Shanghai Pioneer Holding Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Pioneer Holding Ltd have?
Shanghai Pioneer Holding Ltd has 1,257,447,000 shares outstanding.
What happened to Shanghai Pioneer Holding Ltd’s price movement after its last earnings report?
Shanghai Pioneer Holding Ltd reported an EPS of HK$0.063 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.406%.
Which hedge fund is a major shareholder of Shanghai Pioneer Holding Ltd?
Currently, no hedge funds are holding shares in HK:1345
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Pioneer Holding Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.40%
12-Months-Change
Fundamentals
Return on Equity
5.36%
Trailing 12-Months
Asset Growth
6.92%
Trailing 12-Months
Company Description
Shanghai Pioneer Holding Ltd
China Pioneer Pharma Holdings Limited operates as an investment holding company, primarily focusing on the marketing, promotion, and distribution of pharmaceutical goods and medical devices within mainland China. The firm maintains an extensive portfolio of pharmaceutical products addressing diverse therapeutic areas, including ophthalmology, pain management, cardiovascular health, immunology, gynecology, and gastroenterology. Its medical device offerings encompass solutions for ophthalmology, orthopedics, dentistry, and wound care. The company supplies its products to a wide client base, including hospitals, various medical institutions, and pharmacies. Additionally, it engages in the sale of supporting tools, leases related equipment, provides dental apparatus, and distributes imported prescription products under license. Established in 1996, China Pioneer Pharma Holdings Limited is headquartered in Shanghai, PRC, and functions as a subsidiary of Pioneer Pharma (BVI) Co., Ltd.
Technical Analysis
Peijia Medical Ltd.
―
Acotec Scientific Holdings Limited
―
MicroPort CardioFlow Medtech Corp.
―
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H
―
Zhejiang Taimei Medical Technology Co Ltd Class H
―